АНАЛИЗ АНТИДЕПРЕССАНТОВ, ПРЕДСТАВЛЕННЫХ НА  ФАРМАЦЕВТИЧЕСКОМ РЫНКЕ КЫРГЫЗСКОЙ РЕСПУБЛИКИ

A. Kubanychbek k; A.A. Zurdinova

doi:10.54890/.v1i1.1286

A. Kubanychbek k A.A. Zurdinova

DOI:

https://doi.org/10.54890/.v1i1.1286

Abstract

Mental disorders make up a significant part of the overall global burden of disease, with depression and anxiety among the top ten main causes leading to disability between the ages of 10 and 49. Due to the fact that antidepressants are mainly used in the pharmacotherapy of depression and anxiety disorders, the purpose of our research was to segment the pharmaceutical market of antidepressants in the Kyrgyz Republic. The database of the State Register of Medicines of the Department of Medicines and Medical Devices of the Ministry of Health of the Kyrgyz Republic, registered and approved for medical use in the Kyrgyz Republic, was used for the analysis. The methods of content analysis, observation, comparison, grouping, and ranking were used. Currently, 24 drugs from the group of antidepressants are officially approved for medical use in the Kyrgyz Republic. The maximum number of deliveries to the country in monetary terms was carried out in 2021, amounting to 42 210 339 soms or 496,523 USA dollars. The sales leaders from the antidepressant group are the drugs amitriptylline, paroxetine (rexetin®) and escitalopram (sevpram®). The study identified problems with the physical availability of antidepressants in the country.

Keywords:

psychotropic drugs, range of antidepressants, physical accessibility.

Author Biographies

A. Kubanychbek k, Kyrgyz-Russian Slavic University named after B.N.Yeltsin

Department of basic and clinical pharmacology

A.A. Zurdinova, Kyrgyz-Russian Slavic University named after B.N.Yeltsin

Department of basic and clinical pharmacology

References

1. Forns J, Pottegard A, Reinders T, Poblador-Plou B, Morros R, Brandt L, et al. Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: incidence and comorbidities of antidepressant initiators. J Affect Disord. 2019;249:242–52. https://doi.org/10.1016/j.jad.2019.02.010

2. Mars B, Heron J, Kessler D, Neil M Davies 2 3, Martin RM, Thomas KH, et al. Influences on antidepressant prescribing trends in the UK: 1995-2011. Soc Psychiatry Psychiatr Epidemiol. 2017;52:193–200. https://doi.org/10.1007/s00127-016-1306-4

3. Голенков А.В. Основы психиатрии: синдромы и психотропные средства. Чебоксары: Изд Чувашского унив. 2019. 104 c. [Golenkov A.V. Osnovy psihiatrii: sindromy i psihotropnye sredstva. Cheboksary: Izd Chuvashskogo univ. 2019. 104 p. (In Russ.)].

4. Данилов Д.С. Антидепрессанты – ингибиторы обратного захвата серотонина и норадреналина: взгляд через призму 30-летней истории. Неврол, нейропсих, психосом. 2018;10(4):4-12. [Danilov D.S. Serotonin and norepinephrine reuptake inhibitor antidepressants: a look through the prism of their 30-year history. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):4-12. (In Russ.)]. https://doi.org/10.14412/2074-2711-2018-4-4-12

5. Данилов Д.С. История трициклических антидепрессантов и ее значение для современной психофармакотерапии. Социальная и клиническая психиатрия. 2019;29(2):65–78. [Danilov D.S. History of tricyclic antidepressants and its impact on current psychopharmacotherapy. Social and Clinical Psychiatry. 2019;29(2):65–78. (In Russ.)].

6. Любов Е.Б., Васькова Л.Б., Тяпкина М.В., Мусина Н. Уровни суицидов и потребление антидепрессантов в России и её регионах. Суицидология.2017;8(2):49–53. [Lyubov E.B., Vas'kova L.B., Tyapkina M.V., Musina N. Suicide rates and antidepressant utilization in Russia аnd its regions. Suicidology. 2017;8(2):49–53. (In Russ.)].

7. Департамент лекарственных средств и медицинских изделий МЗ КР. Государственный Реестр лекарственных средств Кыргызской Республики. Доступно по: https://www.pharm.kg/ru/registry. [Departament lekarstvennyh sredstv i medicinskih izdelij MZ KR. Gosudarstvennyj Reestr lekarstvennyh sredstv Kyrgyzskoi Respubliki. Available from: https://www.pharm.kg/ru/registry. (In Russ.)].

8. Централизованный банк данных правовой информации Кыргызской Республики. Перечень жизненно-важных лекарственных средств Кыргызской Республики. 2018;(274). Доступно по: http://cbd.minjust.gov.kg/act/view/ru-ru/11924 [Centralizovannyj bank dannyh pravovoj informacii Kyrgyzskoj Respubliki. Perechen' zhiznenno-vazhnyh lekarstvennyh sredstv Kyrgyzskoi Respubliki. 2018;(274). Available from: http://cbd.minjust.gov.kg/act/view/ru-ru/11924. (In Russ.)].

9. Централизованный банк данных правовой информации Кыргызской Республики. Справочник ЛС, возмещаемых по Дополнительному перечню обязательного медицинского страхования (ДПОМС). Доступно по: http://cbd.minjust.gov.kg/act/view/ru-ru/98211 [Centralizovannyj bank dannyh pravovoj informacii Kyrgyzskoj Respubliki. Spravochnik LS, vozmeshchaemyh po Dopolnitel'nomu perechnyu obyazatel'nogo medicinskogo strahovaniya (DPOMS). Available from: http://cbd.minjust.gov.kg/act/view/ru-ru/98211. (In Russ.)].